Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Revenue (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Revenue for 1 consecutive years, with -$9000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Revenue changed N/A year-over-year to -$9000.0, compared with a TTM value of -$9000.0 through Sep 2025, up 99.86%, and an annual FY2022 reading of $705000.0, down 61.03% over the prior year.
  • Revenue was -$9000.0 for Q4 2024 at Summit Therapeutics, up from -$3.1 million in the prior quarter.
  • Across five years, Revenue topped out at -$9000.0 in Q4 2024 and bottomed at -$3.1 million in Q1 2024.